Delivery Order SPE2DB25D3306-SPE2DB25FUCRM
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $53,038 on August 20, 2025, for the supply of SCEMBLIX 40 mg tablets (60-count units) under a firm fixed-price contract with no set-aside designation. The order, which carries an ultimate completion date of September 11, 2025, is funded through the Defense Logistics Agency's Medical Supply Chain and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 31, 2025, for SCEMBLIX 40 mg tablets in quantities of 60 units. The contract is valued at $13,259.50 under a firm fixed-price arrangement with a completion date of August 21, 2025. This award represents a competitive procurement with no set-aside designation and serves as a child contract under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of SCEMBLIX 40 mg tablets in quantities of 60 units, valued at $13,259.50. This non-competitive, firm fixed-price delivery order was awarded on July 31, 2025, with an ultimate completion date of August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) on August 7, 2025, with an ultimate completion date of August 28, 2025. The contract utilizes firm fixed price terms and was awarded through open competition with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, performed as the prime contractor for this pharmaceutical delivery. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 units of Scemblix 40 mg tablets, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,259.50 fixed-price contract is for the delivery of SCEMBLIX 40 MG TABLET UU 60S, a specialty medication. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Scemblix 40 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract with no set-aside designation is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Scemblix is a prescription medication used in the treatment of chronic myeloid...
- This is a $13,259.50 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SCEMBLIX 40 MG TABLET medical products, with a period of performance through July 28, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $24,304.14 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of SCEMBLIX 40 MG TABLET UU 60S pharmaceutical product. This delivery order contract has an ultimate completion date of April 11, 2024. AmerisourceBergen Drug Corp is the prime contractor and there is no set-aside designation for this award. This delivery order is placed against an indefinite...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCRMDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency for SCEMBLIX 40 mg tablets in a quantity of 60 units. The contract, issued on August 20, 2025, carries a ceiling value of $13,259.50 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 11, 2025. This award was made without a set-aside designation, indicating it was competitively awarded. The contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 through December 2026 that enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally. This delivery order supports the Defense Logistics Agency's medical supply chain operations, which procures pharmaceuticals and medical commodities for the Department of Defense, Defense Health Agency, and other federal healthcare systems. SCEMBLIX is a specialty pharmaceutical product used in the treatment of chronic myeloid leukemia, reflecting DLA's role in providing critical therapeutic medications for military beneficiaries and service members. AmerisourceBergen's performance under this delivery order demonstrates the company's continued capacity to fulfill federal pharmaceutical procurement requirements through its established vendor relationship with DLA and positions the company as a key provider within the Pharmaceutical Prime Vendor program framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 8/20/25 |